Anzeige
Erschienen in:
01.09.2008 | Short Communication
Imatinib inhibition of fludarabine uptake in T-lymphocytes
Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2008
Einloggen, um Zugang zu erhaltenAbstract
Purpose
We investigated the potential drug–drug interaction between imatinib and fludarabine, which may be concomitantly administered in chronic myeloid leukemia (CML) patients receiving fludarabine-based conditioning for allogeneic hematopoietic cell transplantation (HCT). Imatinib is an inhibitor of human equilibrative transporters (hENTs), which are responsible for the intracellular uptake of fludarabine.
Methods
Intracellular accumulation of fludarabine triphosphate (F-ara-ATP), the active metabolite of fludarabine, was measured in CD4+ and CD8+ T-lymphocytes isolated from healthy volunteers, which were treated in vitro with fludarabine alone, and in the presence of either imatinib or NBMPR, a known hENT inhibitor.
Results
Imatinib significantly inhibited F-ara-ATP accumulation in CD4+ and CD8+ T-lymphocytes in a concentration-dependent manner. The observed imatinib inhibition was comparable to inhibition observed with NBMPR. The inhibition of F-ara-ATP by imatinib is likely due to inhibition of nucleoside transporters hENT1 and hENT2.
Conclusions
There is significant in vitro drug interaction between imatinib and fludarabine. This effect may be of important consideration in patients receiving fludarabine-based conditioning prior to HCT.